课题组长

庄光磊，博士，研究员，博士生导师

研究方向

肿瘤高通量测序与克隆进化

肺癌卵巢癌的分子机制和靶向治疗

团队成员

景莹 （助理研究员）

张振峰 （助理研究员）

刘锦 （助理研究员）

蔡梅春 （助理研究员）

马鹏飞 （助理研究员）

张生哲 （博士研究生）

师凯旋 （博士研究生）

沈佩烨 （博士研究生）

逯海娇 （博士研究生）

彭慧昕 （博士研究生）

贾晨强 （博士研究生）

代表性论文

1.      Zhang S., Zhang M., Jing Y., Yin X., Ma P., Zhang Z., Wang X., Di W., Zhuang G. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 

2.      Jing Y., Zhang R., Ma P., Cai M.C., Zhuang G.*, Chen H*. Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. J Pathol. (co-corresponding author)

3.      Ma P., Fu Y., Cai M.C., Yan Y., Jing Y., Zhang S., Chen M., Wu J., Shen Y., Zhu L., Chen H.Z., Gao W.Q., Wang M., Gu Z., Bivona T.G., Zhao X.*, Zhuang G*. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. (co-corresponding author)

4.      Yin X., Jing Y., Cai M.C., Ma P., Zhang Y., Xu C., Zhang M., Di W.*, Zhuang G*. Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer. Cancer Res. (co-corresponding author)

5.      Zhang Z., Peng H., Wang X., Yin X., Ma P., Jing Y., Cai M.C., Liu J., Zhang M., Zhang S., Shi K., Gao W.Q., Di W., Zhuang G. Preclinical efficacy and molecular mechanism of targeting CDK7-dependent transcriptional addiction in ovarian cancer. Mol Cancer Ther.

6.      Zhang M.*, Zhuang G.*, Sun X., Shen Y., Wang W., Li Q., Di W. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol. (co-first author)

7.      Yin X., Wang X., Shen B., Jing Y., Li Q., Cai M.C., Gu Z., Yang Q., Zhang Z., Liu J., Li H., Di W.*, Zhuang G. * A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep. (co-corresponding author)

8.      Ma P., Fu Y., Chen M., Jing Y., Wu J., Li K., Shen Y., Gao J.X., Wang M., Zhao X.*, Zhuang G. * Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway. Theranostics. (co-corresponding author)

9.      Zhang Z., Ma P., Jing Y., Yan Y., Cai M.C., Zhang M., Zhang S., Peng H., Ji Z.L., Di W., Gu Z., Gao W.Q., Zhuang G. BET bromodomain inhibition as a therapeutic strategy in ovarian cancer by downregulating FoxM1. Theranostics.

10.   Jing Y., Zhang Z., Ma P., An S., Shen Y., Zhu L., Zhuang G. Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget.

11.   Zhang S., Jing Y., Zhang M., Zhang Z., Ma P., Peng H., Shi K., Gao W.Q.*, Zhuang G.* Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep. (co-corresponding author)

12.   Zhang M., Zhuang G., Sun X., Shen Y., Zhao A., Di W. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res.

13.   Zhuang G., Ferrara N. The VEGF Receptor Family. Receptor Tyrosine Kinases: Family and Subfamilies (Book chapter).

14.   Zhu H.H.*, Zhuang G.*, Gao W.Q. A candidate gastric stem/progenitor cell marker revealed by genome wide analysis. J Pathol. (co-first author)

15.   Zhang Z., Zhang S., Ma P., Jing Y., Peng H., Gao W.Q.*, Zhuang G.* Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis. (co-corresponding author)

16.   Sun Y., Daemen A., Hatzivassiliou G., Arnott D., Wilson C., Zhuang G., Gao M., Liu P., Boudreau A., Johnson L., Settleman J. Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab.

17.   Li X., Liu Y., Chen W., Fang Y., Xu H., Zhu H., Chu M., Li W., Zhuang G.*, Gao W.Q.* TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. (co-corresponding author)

18.   Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells. Cancer Cell.

19.   18. Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., Ouyang W., Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature Medicine.

20.   Sampath D., Oeh J., Wyatt S.K., Cao T.C., Koeppen H., Eastham-Anderson J., Robilard L., Ho C.C., Ross J., Zhuang G., Reslan H.B., Vitorino P., Barck K.H., Ungersma S.E., Vernes J.M., Caunt M., Van Bruggen N., Ye W., Vijapurkar U., Meng Y.J., Ferrara N., Friedman L.S., Carano R.A. Multi-modal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an anti-vascular response. Neoplasia.

21.   Brauer M.J.*, Zhuang G.*, Schmidt M.*, Yao J., Wu X., Kaminker J.S., Jurinka S.S., Kolumam G., Chung A.S., Jubb A., Modrusan Z., Ozawa T., James C.D., Phillips H., Haley B., Tam R.N., Clermont A.C., Cheng J.H., Yang S.X., Swain S.M., Chen D., Scherer S.J., Koeppen H., Yeh R.F., Yue P., Stephan J.P., Hedge P., Ferrara N., Singh M., Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clinical Cancer Research. (co-first author)

22.   Zhuang G.*, Yu K.*, Jiang Z., Chung A.S., Yao J., Ha C., Toy K., Soriano R., Haley B., Blackwood E., Sampath D., Bais C., Lill J.R., Ferrara N. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Science Signaling. (co-first author)

23.   Phan V.T., Wu X., Cheng J.H., Sheng R.X., Chung A.S., Zhuang G., Tran C., Song Q., Kowanetz M., Sambrone A., Tan M., Meng Y.G., Peale F.V., Junttila M.R., Ferrara N. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A. 

24.   Zhuang G.*, Song W.*, Amato K., Hwang Y., Lee K., Boothby M., Ye F., Guo Y., Shyr Y., Lin L., Carbone D.P., Brantley-Sieders D.M., Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. Journal of the National Cancer Institute. (co-first author)

25.   Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Qu X., Guan Y., Oeh J., Modrusan Z., Bais C., Sampath D., Ferrara N. Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. The EMBO Journal.

26.   Chung A.S., Kowanetz M., Wu X., Zhuang G., Ngu H., Finkle D., Komuves L., Peale F., Ferrara N. Differential drug-class specific metastatic effects following treatment with a panel of angiogenesis inhibitors. The Journal of Pathology.

27.   Qu X., Zhuang G., Yu L., Meng G., Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. The Journal of Biological Chemistry.

28.   Yao J., Wu X., Zhuang G., Kasman I.M., Vogt T., Phan V., Shibuya M., Ferrara N., Bais C. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A.

29.   Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., Jackson D., Muraoka-cook R.S., Arteaga C.L., Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Research.

30.   Brantley-Sieders D.M., Zhuang G., Vaught D., Freeman T., Hwang Y., Hicks D., Chen J. Host-deficiency in Vav 2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Molecular Cancer Research.

31.   Chen J., Zhuang G., Frieden L., Debinski W. Eph receptors and Ephrins in Cancer: Common Themes and Controversies. Cancer Research.

32.   Fang W.B., Ireton R.C., Zhuang G., Takahashi T., Reynolds A., Chen J. Overexpression of EphA2 receptor destabilizes adherens junction via a RhoA-dependent mechanism. Journal of Cell Science.

33.   Brantley-Sieders D.M.*, Zhuang G.*, Hicks D., Fang W.B., Hwang Y., Cates J.M., Coffman K., Jackson D., Bruckheimer E., Muraoka-Cook R.S., Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. The Journal of Clinical Investigation. (co-first author)

34.    Zhuang G., Hunter S., Hwang Y., Chen J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. The Journal of Biological Chemistry.

35.   Hunter S.G., Zhuang G., Brantley-Sieders D., Swat W., Cowan C.W., Chen J. Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Molecular and Cellular Biology.

36.   Brantley-Sieders D.M., Fang W.B., Hicks D.J., Zhuang G., Shyr Y., Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. The FASEB Journal.

所获项目

1. 国家自然科学基金面上项目， 2017/01-2020/12

2. 上海青年科技启明星计划，2016/01-2018/12

3. 上海高校特聘教授（东方学者），2015/06-2018/05

4. 国家自然科学基金面上项目，2015/01-2018/12

5. 美国国防部乳腺癌项目博士研究基金，2008/01-2010/12